BioTech Navigator Investment Newsletter 01 01 News Color Page 9
9
N
othing herein should be construed as an offer to buy or sell any security. It should not be assumed that recommendations will b
e profitable or will equal the pe
r-
formance of other securities mentioned or recommended in the past or that chart, formula, theory or method can guarantee profits
. Recommendations and advice
are given with the understanding that the reader assumes all risks involved and that the publisher
is not making any guarantee as to any predicted results.
BioTech Sage Report, January 2001
9
Symbol
52 Wk
52 Wk
Price
M
arket
E
arnings
P
er
S
hare
Product
Clinical
Insmed Inc.
INSM
NA
49.00
2.56
3.47
113.3M
-
2.16 NA
SomatoKine
Severe Burns
Phase II
Lifecell
LIFC
NA
12.63
1.25
1.63
27.1M
-
.83
-
.50
Alloderm
Plastic and
reconstructive
Market
Lifecore
Biomedical Inc
LCBM
NA
23.75
3.38
4.25
53.6M
-
.13
-
.11
Intergel
Prevents
NDA
Magainin
MAGN
NA
10.69
1.13
2.19
70.9M
-
.52 NA
Locilex
Diabetic foot
Phase III
Novartis
NVS
29.5
44.69
34.63
44.88
117.3B
1.58 NA
TGF
-
Beta 3
Wound healing
Phase I
Organogenesis
ORG
NA
27.37
6.76
8.40
289.7M
-
.93
-
.67
Apligraf
Graftpatch
Venous ulcers
Severe burns
Market
Phase II
Ortec International
ORTC
NA
17.00
5.38
5.63
54.4M
-
1.51
-
1.24
Composite cultured skin
Severe wounds
Phase III
OSI
OSIP
NA
83.38
5.88
79.19
2.66B
-
.67
-
.52
TGF
-
Beta 3
Wound healing
Phase II
Regeneration
REGN
NA
57.38
9.88
36.50
1.34B
-
.74
-
.74
Allografts
Bone and tissue
Market
Scios
SCIO
NA
23.56
3.38
22.19
845.8M
-
.53
-
1.12
Fiblast
recalcitrant de
r-
Phase III
Stem Cells
STEM
NA
20.00
1.25
2.38
49.6M
-
.84 NA
Stem Cells
Neural, liver
Research
